89bio reports news as a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. Its recurring updates center on pegozafermin, an engineered fibroblast growth factor 21 analog using glycoPEGylated technology, and its clinical development for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
Company news also covers operating and financial results, clinical and regulatory disclosures, investor conference participation, Nasdaq inducement equity grants, governance matters, material agreements and capital-structure updates tied to its public-company status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.